Search Results

You are looking at 1 - 10 of 49 items for :

  • All content x
Clear All
Open access

Eline van der Valk, Tom Tobe, Aline Stades, and Alex Muller

Background Acromegaly is a multisystem disease with rheumatological, cardiovascular, respiratory and metabolic consequences (1) . A frequent metabolic consequence is hypercalciuria (2) (3) . Although several studies have been published on

Open access

C Mumby, J R E Davis, J Trouillas, and C E Higham

test, GH levels suppressed normally (nadir 0.07 ng/ml) with an IGF1 level in the reference range of 111 ng/ml, confirming successful treatment of the acromegaly. Histology of the adrenal tissue demonstrated a well-circumscribed and encapsulated oval

Open access

Melissa H Lee, Penelope McKelvie, Balasubramanian Krishnamurthy, Yi Yuen Wang, and Carmela Caputo

Background Acromegaly is most commonly due to a growth hormone (GH)-secreting pituitary adenoma arising from somatotroph cells, with a minority (<2%) of cases due to growth hormone-releasing hormone (GHRH) hypersecretion ( 1 ). Mixed pituitary

Open access

Ekaterina Manuylova, Laura M Calvi, Catherine Hastings, G Edward Vates, Mahlon D Johnson, William T Cave Jr, and Ismat Shafiq

, however, follow-up screening is not generally recommended ( 3 ). Here, we present two patients with well-controlled prolactinoma on dopamine agonists, who each developed clinical and biochemical evidence of acromegaly 
many years after the initial

Open access

Cristina Alvarez-Escola and Jersy Cardenas-Salas

Background Acromegaly is a rare, severe systemic disease caused by a growth hormone (GH)-secreting pituitary adenoma, which leads to the excessive production of both GH and insulin-like growth factor 1 (IGF1). The mainstay of treatment is

Open access

Shweta Birla, Sameer Aggarwal, Arundhati Sharma, and Nikhil Tandon

haploinsufficiency (3) . We report here a novel deleterious genetic finding in a patient with CNC who presented with recurrent left atrial myxoma and acromegaly. Case presentation A 30-year-old male, surgically operated for recurrent left atrial myxoma

Open access

E Sanz-Sapera, S Sarria-Estrada, F Arikan, and B Biagetti

secondary to hypopituitarism (hypocortisolism) or, rarely, to inappropriate antidiuretic hormone (ADH) secretion ( 7 ). We report the rare case of a patient with a previously undiagnosed and untreated acromegaly, which presented with pituitary apoplexy

Open access

Nikolaos Kyriakakis, Jacqueline Trouillas, Mary N Dang, Julie Lynch, Paul Belchetz, Márta Korbonits, and Robert D Murray

Background Acromegaly is characterised by typical skeletal changes, with coarsened facial features, pronounced growth of hands and feet, soft tissue hypertrophy and a wide range of systemic clinical features involving the cardiovascular

Open access

Anne Marie Hannon, Isolda Frizelle, George Kaar, Steven J Hunter, Mark Sherlock, Christopher J Thompson, Domhnall J O’Halloran, and the Irish Pituitary Database Group

Background Acromegaly is a rare disease characterised by excessive growth hormone production. Subfertility is common in acromegaly and has various aetiologies, both as a result of the pituitary adenoma and also due to the treatments involved

Open access

Athanasios Fountas, Shu Teng Chai, John Ayuk, Neil Gittoes, Swarupsinh Chavda, and Niki Karavitaki

are associated with significant morbidity and mortality making them one of the most challenging tumours to manage ( 2 ). Acromegaly is also a rare condition with prevalence of 2.8–13.7 cases/100 000 people and annual incidence of 0.2–1.1 cases/100 000